REGENXBIO Inc. (NASDAQ: RGNX) is a Healthcare company (Biotechnology) with a market capitalization of $479M. The Maz Rating grades it against the other companies in its sector.
REGENXBIO Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.24, REGENXBIO Inc. trades at 3.1x sales and 3.2x book value. Over the last twelve months it generated about $155M of revenue and a net loss of $214M. It runs a gross margin of 87.5%, an operating margin of -95.7% and a net margin of -113.9%. It shows return on equity of -204.0%, return on invested capital of -36.4% and a free cash flow yield of -32.3%. On the balance sheet: a debt-to-equity ratio of 0.45 and a current ratio of 4.74. Over the past 52 weeks the share price ranged from $5.46 to $16.19, with a beta of 0.93.
REGENXBIO Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 1 Strong Buy, 12 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.